Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries

NCT ID: NCT04565925

Last Updated: 2025-12-16

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-07-07
• Study Completion Date: 2026-12-01

Brief Summary

The goal of this study is to determine whether administration of sildenafil will decrease urine leakage in patients with spinal cord injuries.

Detailed Description

Spinal cord injury (SCI) is a devastating condition affecting 291,000 women and men in the US alone. Urinary incontinence (UI) is a common problem in these patients, affecting 52% of the population, with episodes of incontinence occurring daily in 20-27% of affected persons. UI after spinal cord injury (SCI) is a major cause of distress and morbidity amongst patients with SCI, and is associated with decreased quality of life in general, physical, and emotional domains. UI has the undesirable side effects of perineal irritation and infection, increased odor, disrupted sleep, embarrassment, need to change clothes/bedding, and sexual dysfunction, as well as significant financial burden. Persons living with a SCI have ranked urinary problems as the most important health problem after injury. Addressing this significant problem and providing relief has the potential to significantly improve the lives of patients with SCI.

Typical treatment options are geared toward the type of UI in each patient. For stress UI, the goal of treatment is to provide support to the pelvic floor and urethra. Pessaries (devices placed inside the vagina in women) or surgery (e.g. suburethral sling) to elevate the urethra and/or bladder neck to increase the resistance to leak through the urethra are commonly used. Urethral bulking agents or pelvic muscle floor therapy are also employed to strengthen the closure pressure of the urethra in patients with stress UI. No pharmacologic agents are currently available to treat stress UI. For urge UI, medications or electrical stimulation aimed at relaxation of the detrusor muscle, including anticholinergics, are used. For overflow or obstructive UI, treatments are aimed at shrinking or removing the obstruction, such as medications to shrink the prostate, prostatectomy or mass removal. For neurogenic UI, surgery for diversion or implant placement may be utilized.

Sildenafil (Viagra) has been well studied and used extensively in males to treat erectile dysfunction. Phosphodiesterase 5 (PDE5) inhibitors, including sildenafil, are potent vasodilators that enhance tissue perfusion, relax smooth muscle of the vasculature and bladder, and stimulate skeletal muscle protein synthesis. It has been reported to improve lower urinary tract symptoms, including urge UI and benign prostatic hyperplasia (BPH) in men. In our team's recent study using sildenafil for treatment of UI in women, the investigators found improvement in quality of life and a decrease in the number of incontinence episodes in women taking sildenafil. Higher sildenafil plasma levels were associated with greater improvement in symptoms. While the types of UI in women are somewhat different than in men, studies have shown improvements in UI in both sexes.

Thus, the investigators propose to conduct a two month randomized, placebo-controlled crossover trial of sildenafil in male and female adult SCI patients with UI to assess the therapeutic potential of sildenafil to reduce the symptoms of urinary leakage.

Aims:

Aim 1: To determine whether sildenafil will decrease episodes of leakage of UI in adult women and men with SCI.

Aim 2: To determine the effects of sildenafil on the subjective measures of UI, including quality of life.

Experimental Protocol:

Investigators will study patients with spinal cord injuries (aged 18-70) with current urine leakage of more than 3 times/week (n=24). Subjects will undergo a double blinded randomized cross over treatment of sildenafil (20mg TID) and placebo. Each treatment period will last 4 weeks with a 2 week washout between treatment periods.

Before and after each treatment period, subjects will undergo testing which will consist of measurements of urine post void residual volume (PVR), adverse event assessment, and questionnaires of quality of life and urinary health.

Conditions

Spinal Cord Injuries; Urinary Incontinence

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Sildenafil 20mg TID then Placebo TID

Subjects will be administered Sildenafil 20mg TID for 4 weeks. There will be a 2 week washout period then subjects will be administered Placebo (lactose) TID for 4 weeks.

Group Type: EXPERIMENTAL

Sildenafil Citrate

Intervention Type: DRUG

Sildenafil 20mg TID for 4 weeks

Placebo

Intervention Type: DRUG

Placebo (Lactose) TID for 4 weeks

Placebo TID then Sildenafil 20mg TID

Subjects will be administered Placebo (lactose) TID for 4 week. There will be a 2 week washout period and then subjects will be administered Sildenafil 20mg TID for 4 weeks.

Group Type: EXPERIMENTAL

Sildenafil Citrate

Intervention Type: DRUG

Sildenafil 20mg TID for 4 weeks

Placebo

Intervention Type: DRUG

Placebo (Lactose) TID for 4 weeks

Interventions

Sildenafil Citrate

Sildenafil 20mg TID for 4 weeks

Intervention Type: DRUG

Placebo

Placebo (Lactose) TID for 4 weeks

Intervention Type: DRUG

Other Intervention Names

Revatio; Lactose

Eligibility Criteria

Inclusion Criteria

• Adults with spinal cord injury (SCI), 18-75 years of age, at the time of consent
• Have urinary incontinence (UI), with at least 3 leakage episodes/week
• Have urodynamics assessment on file with their provider in past 3 years. If no historical data on file, subject may complete prior to study visit 1.
• Willing and able to comply with study procedures
• Willing and able to provide written informed consent

Exclusion Criteria

• In phone prescreen, delighted or pleased with current quality of life due to urinary symptoms.
• Indwelling catheter
• History of greater than 4 urinary tract infections per year
• Multiple sclerosis
• Significant heart, liver, kidney, pulmonary, blood, autoimmune or peripheral vascular disease
• Systolic blood pressure <90 or >170, diastolic blood pressure <50 or >110 after repeated evaluation with proper cuff. This range is the acceptable range stated in the prescribing information for sildenafil (>90/50 and <170/110)
• Active cancer
• HIV, Hepatitis B, or Hepatitis C
• Use of systemic nitrates, anabolic steroids, corticosteroids, or long acting PDE5 inhibitors in the past 1 month
• Use of short acting PDE5 inhibitors in the past 1 week
• Use of alpha blockers, anticholinergic agents, bethanechol, or other UI treatment within the past 2 weeks ( 3 weeks for long acting muscarinic receptor antagonists)
• Known allergic reaction to any agent under investigation or required by the protocol
• Females who are pregnant or lactating
• Atonic bladder or high detrusor and high pelvic floor muscle pressure based on previous cystometrogram (CMG) (on file with their provider) that would place subjects at risk for kidney injury
• Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The University of Texas Medical Branch, Galveston

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kathy Vincent, MD

Role: PRINCIPAL_INVESTIGATOR

University of Texas

Locations

Texas A&M University

College Station, Texas, United States

Site Status: ACTIVE_NOT_RECRUITING

University of Texas Medical Branch

Galveston, Texas, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Kate M Randolph, BS

Role: CONTACT

kmrandol@utmb.edu

409-223-7891

Kathy Vincent, MD

Role: CONTACT

klvincen@utmb.edu

409-772-2610

Facility Contacts

Kathleen Vincent, MD

Role: primary

klvincen@utmb.edu

409-772-2610

Lauren Dawson, BS

Role: backup

lndawson@utmb.edu

409-354-9792

Other Identifiers

20-0197

Identifier Type: -

Identifier Source: org_study_id